Pharma: Other News To Note
Wednesday, April 10, 2013
Ipsen SA, of Paris, said Health Canada granted marketing authorization for Dysport (botulinum toxin Type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines in adults younger than 65.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.